{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T03:51:22Z","timestamp":1777866682820,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dev Pharmacol Ther"],"abstract":"<jats:p>Patent ductus arteriosus (PDA) in premature infants is a current challenge to\npediatricians. Pharmacological closure of PDA with indomethacin, a prostaglandin synthetase\ninhibitor is an effective drug therapy, along with usual medical treatment. Administration\nof indomethacin may decrease mortality and morbidity (e.g. bronchopulmonary dysplasia)\namong very small premature infants (&lt; 1,000 g). Co-administration of furosemide with\nindomethacin may lessen the transient renal side effects of indomethacin. The therapeutic\nefficacy of indomethacin in closure of PDA depends largely on understanding and manipulation\nof the pharmacokinetic characteristics of the drug in preterm infants. Maintaining a\ntherapeutic level of the drug in plasma is essential to achieve an optimal therapeutic\nresponse. Compared to surgical ligation, indomethacin is a noninvasive, less expensive and\nsafer therapy for ductus closure.<\/jats:p>","DOI":"10.1159\/000457690","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:08:51Z","timestamp":1502471331000},"page":"196-212","source":"Crossref","is-referenced-by-count":15,"title":["Role of Indomethacin in Ductus Closure: an Update Evaluation"],"prefix":"10.1159","author":[{"given":"Samir M.","family":"Douidar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne R.","family":"Snodgrass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["Developmental Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000457690","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:09:17Z","timestamp":1777540157000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000457690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000457690","archive":["Portico"],"relation":{},"ISSN":["0379-8305","2504-2505"],"issn-type":[{"value":"0379-8305","type":"print"},{"value":"2504-2505","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}